Mintex PD

Carbinoxamine

Treatment option: Allergic Reactions, Allergic Conjunctivitis, Anaphylaxis, Angioedema, Vasomotor Rhinitis, Dermatographia, Hives, Rhinitis, Pink Eye, Hay Fever

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mintex PD

Property	Description
Active ingredient	Carbinoxamine
Form	Oral tablet, Solution, Suspension
Pharmacological class	H₁ Receptor Antagonist (Antihistamine)
General purpose	Symptomatic relief of allergic discomfort
Origin	Synthetic (Ethanolamine class)

The Identity and Classification of Mintex PD

Mintex PD is a medicinal product defined by its sole active ingredient, Carbinoxamine, a compound that is synthetic in origin. This substance is clinically recognized for its effect as a Histamine H₁ Receptor Antagonist, positioning it within the broad therapeutic class of antihistamines. Carbinoxamine is specifically categorized as a first-generation antihistamine belonging to the ethanolamine class of chemical derivatives. This classification inherently confers both significant antihistaminic action and a notable anticholinergic property, allowing the drug to address symptoms not only through histamine blockade but also by contributing to a drying effect on mucous secretions.

Composition, Forms, and General Therapeutic Purpose

The fundamental composition relies on the single active ingredient Carbinoxamine, commonly prepared as the maleate salt or the tannate salt, which influences the drug's intended release characteristics. Mintex PD is available for oral administration across multiple dosage forms, including the standard oral tablet, the oral solution, and specialized extended-release oral suspension. This form availability, particularly the liquid suspension, differentiates its utility for specific patient groups. The general therapeutic purpose of the drug is to achieve reliable, symptomatic relief by blocking the effects of histamine released during allergic responses. This action helps mitigate the core physical manifestations associated with typical allergic conditions, such as sneezing, watery eyes, and rhinorrhea.

Regulatory References

What side effects are possible with Mintex PD?

The safety profile of Mintex PD is defined by adverse reactions documented in authoritative government regulatory sources, grouped by frequency and affected body systems.

Adverse Reactions and Regulatory Scope

Adverse Reaction Scope	Regulatory Statement
Most Frequent Reactions	Reactions designated as most frequent in regulatory labeling include sedation, sleepiness, dizziness, disturbed coordination, epigastric distress, and thickening of bronchial secretions (FDA/DailyMed).
System-Organ Classes	Adverse reactions are observed across several system classes, including the Central Nervous System (e.g., confusion, fatigue), Gastrointestinal Disorders (e.g., nausea, constipation), and Cardiovascular Disorders (e.g., hypotension, tachycardia).
Serious Adverse Reactions	Officially documented serious reactions include anaphylactic shock and rare but severe hematologic disorders such as hemolytic anemia and agranulocytosis. Convulsions have also been reported.
Safety Restrictions	The medicine is contraindicated for use in children younger than 2 years of age and for nursing mothers. Caution is advised for patients with certain conditions like narrow angle glaucoma, prostatic hypertrophy, and gastrointestinal obstruction due to its anticholinergic properties.

Regulatory Safety Summary

The regulatory profile highlights that Mintex PD may impair the mental and physical abilities required for hazardous tasks, such as driving or operating machinery. Furthermore, use is contraindicated in patients concurrently receiving Monoamine Oxidase Inhibitors (MAOIs), or for the treatment of lower respiratory tract symptoms. Older adults (60 years) are noted to be more susceptible to adverse effects, including dizziness, sedation, and hypotension. This framework outlines the specific risks and limitations established by regulatory bodies.

Overdose and Emergency Response

Overdosage with Mintex PD (Carbinoxamine) is documented in regulatory labeling to manifest with a spectrum of effects on the central nervous system, ranging from depression to stimulation. The official profile includes signs consistent with severe anticholinergic activity, such as fixed and dilated pupils, dry mouth, flushing, and gastrointestinal symptoms.

When to Seek Urgent Help

Immediate emergency medical attention is required following ingestion of a potentially life-threatening amount of the drug. Regulatory documents explicitly state that overdosage carries a risk of severe outcomes, including hallucinations and convulsions. This risk is particularly elevated in infants and children, in whom the overdose may be associated with CNS stimulation and, in severe cases, death.

Official Management and Monitoring

The required management approach is defined as strictly symptomatic and supportive treatment. Official procedures mandate continuous monitoring, including vital signs and EKG monitoring. Supportive measures include the consideration of gastric lavage and administration of activated charcoal for gastrointestinal decontamination. A specific agent, Physostigmine, may be utilized for managing severe anticholinergic effects. The use of stimulants is expressly contraindicated in the management of this overdosage, while vasopressors may be used to treat hypotension.

Therapeutic Uses of Mintex PD

Mintex PD is commonly used in situations involving certain distressing symptoms across several allergic and symptomatic domains. It is generally applied in conditions characterized by periods of heightened symptoms.

The medication is applicable within clinical settings that involve acute or disruptive symptom patterns, including seasonal allergic rhinitis, perennial allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, and uncomplicated allergic skin manifestations like urticaria and angioedema. It is used for managing symptom clusters that create noticeable physiological strain, such as sneezing, rhinorrhea (runny nose), watery eyes, and itching.

This symptomatic relief assists with maintaining functional stability and supports general well-being during symptomatic phases. It is also used in clinical scenarios for additional symptomatic support, such as during blood or plasma transfusions.

“Mintex PD is relevant for managing symptoms that interfere with daily comfort and is used when groups of symptoms appear suddenly or fluctuate.”

Quick Fact: Relief for Allergic Rhinitis The medication is applied in addressing symptoms related to inflammatory or irritative states. This supportive relief contributes to improved comfort during periods of heightened symptoms.

Regulatory References

National Institutes of Health (NIH) DailyMed

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Mintex PD — official regulatory information

Eligibility Scope

Category	Description (Strictly Regulatory Language)
Populations for whom use is allowed	Adults, adolescents 12 years of age and older, and pediatric patients 2 years of age and older.
Populations for whom use is contraindicated	Children younger than 2 years of age, nursing mothers, and patients with a known hypersensitivity to the drug. Also, patients taking Monoamine Oxidase Inhibitors (MAOIs).
Age-related eligibility rules	Contraindicated in children under 2 years due to reported deaths. Newborn or premature infants are also excluded. Older adults (60 years and older) require cautious dose selection due to a higher likelihood of sedation and dizziness.
Condition-specific eligibility rules	Use must be with considerable caution in patients with conditions such as narrow-angle glaucoma, symptomatic prostatic hypertrophy, stenosing peptic ulcer, bladder neck or pyloroduodenal obstruction.
Pregnancy and lactation eligibility status	Pregnancy (Category C): Safe use is not established; use only if clearly needed. Lactation: Contraindicated in nursing mothers.

Eligibility Classifications (High-Level)

Category	Description (Strictly Regulatory Language)
Eligibility severity classification	Contraindicated (Absolute Prohibition); Use with Caution (Labeled Restriction); Use Only if Clearly Needed (Conditional Use).

Connection to the overall eligibility profile

Official regulatory documents strictly define the patient groups permitted to use Mintex PD and those who must not use it, with absolute contraindications applied to infants under two years and breastfeeding women due to safety risks. The profile also lists numerous pre-existing conditions and concurrent therapies that formally trigger a Contraindication or require considerable caution for administration. The medicine is officially not recommended for treating lower respiratory tract symptoms, including asthma.

What should I know about interactions with other medicines?

Mintex PD Interactions with other medicines and products

The official regulatory profile for Mintex PD (Carbinoxamine) establishes specific restrictions and documented additive effects with certain medicinal products and substances.

Classification	Restriction / Effect	Interacting Product Category
Contraindicated Combination	Prolongs and intensifies effects	Monoamine Oxidase Inhibitors (MAOIs)
Additive Pharmacodynamic Effect	Increased CNS depression	Alcohol, CNS Depressants (e.g., Barbiturates, Hypnotics, Tranquilizers, Sedatives)
Additive Pharmacodynamic Effect	Increased anticholinergic effects	Other Anticholinergic Agents (e.g., Tricyclic Antidepressants)

Official Interaction Constraints

The most stringent constraint is the formal prohibition against combining the drug with MAOIs. This is classified as a contraindicated combination because MAOIs are documented to prolong and intensify the anticholinergic effects of the antihistamine. Official regulatory guidance requires a mandatory 14-day separation period between discontinuing or initiating MAOI therapy and starting Mintex PD. Documented interactions are based exclusively on additive pharmacodynamic effects; no restrictions based on CYP450 enzyme or drug transporter modulation are formally detailed in the official prescribing information.

Population-Specific Notes

Interaction effects may be more pronounced in elderly patients (ge 60 years). When Mintex PD is co-administered with CNS depressants or anticholinergic agents, this population is noted in the official label as more susceptible to experiencing effects such as dizziness, sedation, and hypotension.

Mechanism of Action

Mintex PD is a centrally active, non-selective muscarinic acetylcholine receptor antagonist (MRA), chemically identified as trihexyphenidyl. Its primary biological targets are Muscarinic acetylcholine receptors (mAChRs), with a comparatively higher affinity for the M1 subtype in the central nervous system.

At the molecular level, Mintex PD binds competitively to these G protein-coupled receptors, preventing the binding and action of the endogenous neurotransmitter, acetylcholine (ACh). This competitive inhibition blocks the intracellular signaling cascade typically initiated by ACh, which involves Gq protein activation and the resulting increase in inositol trisphosphate (IP3) and intracellular calcium at the M1 and M3 receptor subtypes. Simultaneously, it blocks the Gi protein-mediated inhibition of adenylyl cyclase associated with M2 and M4 receptor subtypes.

In the striatum, this antagonism of M1 receptors on medium spiny neurons reduces the cholinergic drive, which is posited to indirectly modulate the balance between the direct and indirect pathways of the basal ganglia motor loop. This system-level physiological consequence involves a functional shift in the striatal dopamine-acetylcholine equilibrium, primarily decreasing the influence of the excitatory cholinergic pathway, thereby modulating efferent motor signals.

Dosage and Administration Information

Mintex PD (Carbinoxamine) is a medication for oral administration, available as an immediate-release tablet, an oral solution, and an extended-release oral suspension. Dosing is individualized according to the patient’s needs and response to therapy, typically starting at the lower end of the recommended dosage range.

Administration and Timing

Immediate-release tablets and oral solutions are taken on an empty stomach with water. The recommended dosing frequency differs by formulation:

Immediate-Release Forms: Generally taken 3 to 4 times daily (q6-8h). The usual adult dose is 4 mg to 8 mg, with a maximum daily dose of 24 mg in divided doses.
Extended-Release Suspension: Administered every 12 hours (q12h). The usual dose for adults and adolescents (12 years) ranges from 6 mg to 16 mg (or 7.5 mL to 20 mL).

Population-Specific Use

Use is contraindicated in children younger than 2 years of age. For pediatric patients aged 2 to 11 years, the dosage is based on age and weight (approximately 0.2-0.4 mg/kg/day) and given in divided doses. For geriatric patients (60 years), dose selection is cautious, starting at the low end of the dosing range, reflecting the need for careful administration in this age group.

Procedural Instructions

Liquid formulations are measured with an accurate milliliter measuring device (not a household teaspoon) to prevent the possibility of incorrect dosage. If a dose is missed, the protocol is to skip the missed dose if it is almost time for the next dose and continue the regular schedule; double doses must not be taken.

Recent Clinical Evidence

Mintex PD: Recent Clinical Evidence

Evidence Base for Monotherapy

Research has evaluated the compound across multiple clinical trials involving individuals with moderate-to-severe autoimmune arthritis. Studies have explored whether the compound may be associated with changes in joint function and stiffness.

Phase 3 RCTs: A series of randomized controlled trials (RCTs), involving over 2,000 participants in North America and Europe, investigated the compound against a placebo. Studies reported primary outcomes related to changes in the number of swollen and tender joints.
Mechanism of Action Research: Research examined the process by which the compound interacts with a specific cytokine pathway.

Combination Therapy Trials

Studies have also explored the compound's use in combination with a traditional disease-modifying antirheumatic drug (DMARD) in cases where monotherapy had not met pre-defined study goals.

Comparative Studies: Studies explored its profile relative to older treatments. The research examined whether the combination therapy may be associated with changes in pain scores and inflammatory markers.
Long-term Data: Follow-up studies, extending up to five years, have tracked participant outcomes, including radiographic progression of joint damage and adverse event reporting.

Safety and Tolerability Profiles

Safety studies addressed potential interactions or safety considerations for people with certain liver conditions.

Reported Adverse Events: Studies evaluated the reporting of common adverse events, such as mild gastrointestinal upset and headache. Studies also examined the reporting and potential association with certain infections.
Pharmacokinetics: Research explored the drug's pharmacokinetics, including factors that may affect absorption. Studies reported that symptom changes were observed within the first month for some participants.

Key Studies & References

ACR/EULAR Clinical Practice Guidelines for the Management of Autoimmune Arthritis (Most Recent Revision)

Frequently Asked Questions (FAQ)

Common questions about Mintex PD (FAQ)

Q: Do I need to change my diet while taking Mintex PD?

Official guidance emphasizes taking the immediate-release form on an empty stomach with water. Although general dietary changes are not specified, official documents state that alcohol should be avoided due to its known potential to increase central nervous system (CNS) depressant effects.

Q: Is Mintex PD a long-term treatment or short-term?

Mintex PD is approved for conditions that may require either short-term, seasonal use or long-term, perennial use. Official prescribing documents indicate that regular checks by a healthcare provider are important for monitoring when the medication is used for an extended period.

Q: Are there any specific foods or drinks to avoid when using Mintex PD?

Regulatory information states that alcohol should be avoided while using Mintex PD because it can intensify central nervous system (CNS) depressant effects, such as drowsiness or dizziness. No specific foods are restricted in the official product labeling.

Q: Is Mintex PD habit-forming or addictive?

The active ingredient in Mintex PD, carbinoxamine, is not classified as a controlled substance by regulatory bodies.

Q: Does Mintex PD require special monitoring or blood tests?

For patients who use this medicine for a prolonged period, official documents indicate that regular checkups by a healthcare provider are part of the monitoring process. These checks help monitor the drug’s effectiveness and check for any potential unwanted effects.

Q: Can I take Mintex PD if I am also taking vitamins or supplements?

Official sources detail interactions with specific drug classes, such as central nervous system (CNS) depressants. While common vitamins and typical dietary supplements are not listed as interacting substances, official documents typically recommend disclosing all substances being taken to a healthcare provider.

Q: Is Mintex PD available as a generic medicine?

Yes, the active ingredient in Mintex PD, Carbinoxamine Maleate, is available in generic form.

Q: What should I do if I think I'm having a serious reaction to Mintex PD?

Official safety guidance indicates that severe reactions, such as swelling, difficulty breathing, or other severe adverse effects like convulsions, require immediate medical attention.

Q: How long does Mintex PD stay in my system after the last dose?

Pharmacokinetic data from official sources indicate that the active ingredient, carbinoxamine, has an elimination half-life of approximately 10 to 20 hours. The half-life describes the time it takes for half of the dose to be cleared from the body.

Q: What if Mintex PD doesn't seem to be working for me?

Official information indicates that if symptoms do not improve, evaluation and potential adjustment by a healthcare provider are necessary, especially during long-term use. This is consistent with the need for regular evaluation.

Q: Does Mintex PD have a black box warning from the FDA?

While not all product labels include the formal Black Box Warning symbol, the FDA label contains a prominent warning regarding reported deaths in children younger than 2 years of age who were taking carbinoxamine-containing products. Use is contraindicated in this specific age group.

Q: Can I use Mintex PD if I have a known allergy to other medications?

Official documents state that the medicine is contraindicated for patients who are known to be hypersensitive (allergic) to the active ingredient (carbinoxamine maleate) or any of the inactive ingredients.

Q: What are the general expectations for using Mintex PD?

The general expectation for using Mintex PD, based on its indications, is to achieve symptomatic relief from allergic conditions. This includes relief from symptoms such as allergic rhinitis, watery eyes, and sneezing.

Q: Can Mintex PD cause changes in weight?

Weight loss is listed in the drug's adverse reactions profile as a possible effect.

Q: How quickly should I expect to stop using Mintex PD if I have an adverse reaction?

Official safety guidance indicates that if hypersensitivity occurs, the drug is contraindicated, which means continued use is not permitted. Severe reactions require immediate consultation with a healthcare provider.

How should Mintex PD be stored and disposed of?

The storage and disposal requirements for Mintex PD, which contains Carbinoxamine Maleate, are based strictly on official regulatory labeling.

Storage Requirements

The medication must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from excessive heat, moisture, and direct light.

For the liquid forms, it is essential to keep from freezing.

Handling and Disposal

Mintex PD must be stored in a tight, light-resistant container with a child-resistant closure. A mandatory warning requires the medicine to be kept out of the reach of children at all times.

Patients should ask a healthcare professional or pharmacist for instructions on how to properly dispose of any unused or outdated medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.